Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | USP2 | O75604 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | GRK6 | P43250 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL4540732 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL4960131 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13320224 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL4042 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL11911315 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL12356688 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL18531248 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL22171064 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL20716523 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL21931671 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0591446-B1 | METHOD FOR TREATING HELICOBACTER PYLORI GASTRITIS | HARRIS RICHARD Y (US) | 2000-09-13 | — | — | EP | claimed |
| US-12594252-B2 | Methods for treating inflammatory skin conditions | JOURNEY MEDICAL CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240424003-A1 | PHARMACEUTICAL COMPOSITIONS FOR MINOCYCLINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2024-12-26 | — | — | US | disclosed |
| EP-3886894-B1 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023147011-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS-2 (SARS-COV-2) | VIMU THERAPEUTICS (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230192598-A1 | NOVEL MODIFIED TETRACYCLINES FOR TREATMENT OF ALCOHOL USE DISORDER, PAIN AND OTHER DISORDERS INVOLVING POTENTIAL INFLAMMATORY PROCESSES | TEXAS TECH UNIVERSITY SYSTEM | 2023-06-22 | — | — | US | disclosed |
| US-20230192598-A1 | NOVEL MODIFIED TETRACYCLINES FOR TREATMENT OF ALCOHOL USE DISORDER, PAIN AND OTHER DISORDERS INVOLVING POTENTIAL INFLAMMATORY PROCESSES | TEXAS TECH UNIVERSITY SYSTEM | 2023-06-22 | — | — | US | disclosed |
| US-20230127462-A1 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20230131030-A1 | Methods for treating inflammatory skin conditions | JOURNEY MEDICAL CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230127462-A1 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070166274-A1 | 7-Dimethylamino-6-Demethyl-6-Deoxytetracycline Skin Treatment Kit | ONSET DERMATOLOGICS, LLC | 2007-07-19 | — | — | US | disclosed |
| US-20070166274-A1 | 7-Dimethylamino-6-Demethyl-6-Deoxytetracycline Skin Treatment Kit | ONSET DERMATOLOGICS, LLC | 2007-07-19 | — | — | US | disclosed |
| US-20070166274-A1 | 7-Dimethylamino-6-Demethyl-6-Deoxytetracycline Skin Treatment Kit | ONSET DERMATOLOGICS, LLC | 2007-07-19 | — | — | US | disclosed |
| WO-2006078925-A2 | A TETRACYCLINE METAL COMPLEX IN A SOLID DOSAGE FORM | WARNER CHILCOTT COMPANY, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| EP-0591446-B1 | METHOD FOR TREATING HELICOBACTER PYLORI GASTRITIS | HARRIS RICHARD Y (US) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | TDP1 1636/4885KDM4E 4134/4885USP2 1885/4885 |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | CCL11, SSB, TNF | TDP1 1126/4885KDM4E 3144/4885USP2 1395/4885 |
| US-20230127462-A1 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | OPRD1, RPLP1, ADH1A | TDP1 2017/4885KDM4E 1750/4885USP2 3172/4885 |
| US-20230192598-A1 | NOVEL MODIFIED TETRACYCLINES FOR TREATMENT OF ALCOHOL USE DISORDER, PAIN AND OTHER DISORDERS INVOLVING POTENTIAL INFLAMMATORY PROCESSES | OPRM1, TNF, CD14 | TDP1 2019/4885KDM4E 1237/4885USP2 3589/4885 |
| US-20070166274-A1 | 7-Dimethylamino-6-Demethyl-6-Deoxytetracycline Skin Treatment Kit | TET1, TET3, TRDMT1 | TDP1 121/4885KDM4E 211/4885USP2 1001/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | TDP1 2667/4885KDM4E 4720/4885USP2 1372/4885 |
| US-12594252-B2 | Methods for treating inflammatory skin conditions | CUTA, KRT18, MMP1 | TDP1 2695/4885KDM4E 3451/4885USP2 3188/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | TDP1 4048/4885KDM4E 3261/4885USP2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.